Literature DB >> 17916337

Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice.

Carlijn R Hooijmans1, Coen Graven, Pieter J Dederen, Heikki Tanila, Thomas van Groen, Amanda J Kiliaan.   

Abstract

UNLABELLED: The amount of the glucose transporter type-1 (GLUT-1) is decreased in the hippocampus and cerebral cortex of AD patients. In this study we therefore wanted to investigate the causal relationship between beta-amyloid (Abeta), GLUT-1 and hippocampal atrophy in the brains of young (8 months) and old (18 months) APP/PS1 mice.
METHODS: Abeta and GLUT-1 were visualized immunohistochemically. Abeta load, GLUT-1 amount, capillary density and GLUT-1 amount per capillary density were determined in cortical and hippocampal areas using computer-assisted analysis systems. Hippocampal atrophy was determined by calculating the width of the outer molecular layer of the dentate gyrus (DG).
RESULTS: In 18-month-old APP/PS1 mice we found a reduced GLUT-1 amount in the hippocampus but no differences in capillary density. The DG of these mice contained the highest level of Abeta in combination with hippocampal atrophy, and a reduced GLUT-1 amount per capillary density. At 8 months, no differences were observed. The highest Abeta deposition was found in the DG, although fourfold less compared to 18-month-old mice.
CONCLUSIONS: We conclude that the GLUT-1 amount and capillary density in both wild type and transgenic mice decrease due to ageing. Further, a decreased amount of GLUT-1 is caused by decreased GLUT-1 amount/capillary density and not due to a reduced capillary density. We suggest that Abeta load in the hippocampus precedes the reduction of GLUT-1. A certain level of Abeta must be reached in the hippocampus, before it affects GLUT-1 amount/capillary density leading to further impairment of energy metabolism and hippocampal atrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916337     DOI: 10.1016/j.brainres.2007.08.063

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  43 in total

Review 1.  Metabolic reserve as a determinant of cognitive aging.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

Review 3.  Reflections on glycogen and β-amyloid: why does glycogenolytic β2-adrenoceptor stimulation not rescue memory after β-amyloid?

Authors:  Marie Gibbs
Journal:  Metab Brain Dis       Date:  2014-05-09       Impact factor: 3.584

Review 4.  Energy metabolism and inflammation in brain aging and Alzheimer's disease.

Authors:  Fei Yin; Harsh Sancheti; Ishan Patil; Enrique Cadenas
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

5.  Angiotensin II, hypertension and angiotensin II receptor antagonism: Roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease.

Authors:  Maximilian Wiesmann; Monica Roelofs; Robert van der Lugt; Arend Heerschap; Amanda J Kiliaan; Jurgen Ahr Claassen
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 6.  Overlapped metabolic and therapeutic links between Alzheimer and diabetes.

Authors:  Waqar Ahmad
Journal:  Mol Neurobiol       Date:  2012-09-26       Impact factor: 5.590

7.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939

Review 8.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

Review 9.  Alzheimer's Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies.

Authors:  Jonathan Chang-Cheng Shieh; Pai-Tsang Huang; Yung-Feng Lin
Journal:  Mol Neurobiol       Date:  2020-01-03       Impact factor: 5.590

10.  Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.

Authors:  Danit Mechlovich; Tamar Amit; Orit Bar-Am; Orly Weinreb; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.